Stanley Goldstein

Aug 6, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

OpinionVideoAugust 6, 2024Author(s):,Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway. Video content above is prompted by the following:A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses.

Aug 6, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

Aug 6, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

OpinionVideoAugust 6, 2024Author(s):A panel of experts discuss the positives and negatives in using omalizumab when treating patients with CSU. Video content above is prompted by the following:A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on recommended doses of omalizumab. What do you believe accounts for this high number of patients who are not responding adequately? Patients have to come in for first 3 doses because this a biologic.

Jul 29, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

OpinionVideoJuly 29, 2024Author(s):A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU. Video content above is prompted by the following question(s):Which healthcare specialties are involved in managing patients with CSU, and how can multidisciplinary care be optimized? What are the comorbidities that are most seen in patients with CSU, and how do these affect your management plan?

Jul 29, 2024 | ajmc.com | Brian Keegan |Giselle Mosnaim |Stanley Goldstein |Anitha Shrikhande

Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous UrticariaDr. Goldstein discusses which therapies are typically used initially for CSU patients.